BIOS BioPlus Acquisition Corporation

In remarks at the annual stockholders� meeting, Chairman and Chief Executive Officer, Richard H. Friedman set forth BioScrip�s (NASDAQ: BIOS) 2007 key goals and objectives as well as its growth initiatives. Mr. Friedman was quoted as saying that �For the past year, as we have met head on the challenges of integrating MIM Corporation and Chronimed, it has been my job to restore shareholder value while protecting the reputations, customers, patients and revenue base of our two highly specialized brands.� Mr. Friedman also outlined the Company�s path to BioScrip achieving its growth and profitability expectations for 2007. Commenting on BioScrip�s strategy for driving revenue growth in 2007, Mr. Friedman noted that �BioScrip�s mission is to be the Specialty Pharmaceutical organization that is known for superior, cost-effective management and service in this vital and complex �high touch � high feel� healthcare sector. We will work in partnership with the key industry participants to meet this objective.� �Our strategy will not only grow BioScrip, but define us as a worthy partner among the nation�s largest pharmaceutical companies, payors and physician groups. The next phase of our integration will help make this possible. This phase includes the alignment of our business units with the most growth oriented markets and customers as well as the optimization of operational systems and platforms.� Interested parties may access an audio webcast of Mr. Friedman�s presentation by visiting the investor relations section of the BioScrip website, http://www.BioScrip.com. In other Company news, all nine of the Company�s directors proposed for election to BioScrip�s Board were duly elected at the annual meeting. In other voting, shareholders ratified the selection of Ernst & Young LLP as BioScrip�s independent auditor for 2007. BioScrip, Inc. provides comprehensive pharmaceutical healthcare solutions. We partner with healthcare payors, pharmaceutical manufacturers, government agencies, physicians and patients to deliver cost effective programs in an effort to optimize the quality of patient life. We focus our products and services in two core areas: Specialty pharmaceutical services, both nationally and community-based, and Pharmacy Benefit Management services. Our specialty services capabilities include condition-specific distribution and clinical management programs for individuals living with health conditions such as HIV/AIDS, cancer, immune deficiency, Hepatitis C, Rheumatoid Arthritis, Multiple Sclerosis, transplantation and Crohn's disease. Our pharmacy benefit management programs include benefit plan design, pharmacy network management and sophisticated reporting capabilities. In addition, we have 36 community, mail service and infusion pharmacies across the U.S., providing nationwide access to prescription medications and clinical services. Forward Looking Statements This press release may contain statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the intent, belief or current expectations of the Company, its directors, or its officers with respect to the future operating performance of the Company. Investors are cautioned that any such forward looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward looking statements as a result of various factors. Important factors that could cause such differences are described in the Company's periodic filings with the Securities and Exchange Commission.